Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
MWN-AI** Summary
Anixa Biosciences, Inc. is set to host its 2026 Annual Meeting of Stockholders on March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. This meeting will be accessible to both stockholders and interested non-stockholders. Following the formal business and voting segment, Dr. Amit Kumar, Chairman and CEO, will present a corporate update, showcasing significant recent advancements in the company's oncology pipeline.
Key highlights of the presentation will focus on the Phase 1 ovarian cancer CAR-T trial, which has shown promising survival data and received regulatory approval for an increase in the dose. Additionally, Anixa will share positive final Phase 1 results from its breast cancer vaccine program, which met its primary endpoints with a favorable safety profile and immune responses observed in most participants.
Anixa is a clinical-stage biotechnology company dedicated to innovating cancer treatment and prevention. Their flagship therapy includes liraltagene autoleucel (lira-cel), developed in collaboration with Moffitt Cancer Center. This ovarian cancer immunotherapy utilizes a novel CAR-T approach known as chimeric endocrine receptor-T cell technology, differentiating it from traditional therapies by targeting tumor cells through natural ligands of the FSHR receptor.
Moreover, Anixa is working with the Cleveland Clinic to develop cancer vaccines aimed at treating breast and ovarian cancers, as well as vaccines targeting high-incidence malignancies, including lung, colon, and prostate cancers. The company’s partnership model with leading research institutions enhances its innovation capabilities, allowing continuous development of cutting-edge cancer therapies.
For more details, visit Anixa's website or follow them on social media.
MWN-AI** Analysis
Anixa Biosciences, Inc. (NASDAQ: ANIX) is set to host its 2026 Annual Meeting of Stockholders on March 10, 2026, where critical updates on its oncology pipeline will be shared. The meeting will focus on recent advancements in its clinical trials, particularly surrounding its ovarian cancer CAR-T therapy and breast cancer vaccine, both of which have shown promising results.
The encouraging findings from the Phase 1 ovarian cancer CAR-T trials, especially the approval for dose escalation, signify a pivotal moment for the company. This could potentially attract further investments as it suggests advancements towards efficacy that may lead to regulatory approval for commercial use. The emphasis on therapeutic innovations using chimeric endocrine receptor-T cell technology offers a competitive edge, allowing Anixa to differentiate its treatment modalities in a crowded biopharmaceutical market.
Investors should also take note of the recent data from the breast cancer vaccine program, which has successfully met its primary endpoints and demonstrated favorable tolerability. This success not only reinforces the potential market viability of these vaccines but also enhances Anixa's collaboration profile with institutions like the Cleveland Clinic.
As the company pursues these promising therapies, alongside partnerships with prominent cancer research centers, it may enhance its growth potential and market position. The ongoing quest for sustainable cancer treatments will likely elevate Anixa's standing among biotech investors, particularly those with a focus on innovative oncology solutions.
Given the current landscape, investors should closely monitor developments post-meeting, as progress in clinical trials is often a precursor to greater market interest and potential stock appreciation. However, it is advised to assess risk factors closely, as biotech investments can be volatile and are often subject to regulatory challenges. Overall, the outlook appears cautiously optimistic, with significant opportunities for advancements and strategic partnerships on the horizon.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data
SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.
Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar will deliver an investor presentation and corporate update. The presentation will include a review of recent clinical milestones across the Company's oncology pipeline, including:
- Encouraging survival observations and regulatory approval for substantial dose escalation in the Company's ongoing Phase 1 ovarian cancer CAR-T trial; and
- Final Phase 1 data from the breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and protocol-defined immune responses in the majority of participants.
The presentation will be followed by a live question-and-answer session.
The Meeting may be accessed online at: www.virtualshareholdermeeting.com/ANIX2026
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
SOURCE Anixa Biosciences, Inc.
FAQ**
What specific survival observations can you share from the ongoing Phase 1 ovarian cancer CAR-T trial that demonstrate the efficacy of Anixa Biosciences Inc. ANIX's treatment approach?
Could you provide more details about the regulatory approval for dose escalation in the ovarian cancer CAR-T trial and how it impacts the timeline for Anixa Biosciences Inc. ANIX's clinical development?
Can you elaborate on the significance of the final Phase 1 breast cancer vaccine data and how it aligns with Anixa Biosciences Inc. ANIX's goals for future trials and potential commercialization?
How does Anixa Biosciences Inc. ANIX plan to leverage its collaborations with Moffitt Cancer Center and Cleveland Clinic to enhance its oncology pipeline and address challenges in cancer treatment?
**MWN-AI FAQ is based on asking OpenAI questions about Anixa Biosciences Inc. (NASDAQ: ANIX).
NASDAQ: ANIX
ANIX Trading
1.42% G/L:
$2.86 Last:
53,572 Volume:
$2.93 Open:
